AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 9, 2026 Xenon Reports Q3 2026 Financial Results and Provides Business Update Headline · Source: company release
Nasdaq Global Market: $XENENeuroscience and ion channel therapeutics

XENE Stock Hub: Xenon Pharmaceuticals News, Azetukalner and Epilepsy

Xenon reported third-quarter 2026 results after the U.S. close on November 9, 2026: a net loss of $110.4 million, or $1.11 per share, on research and development expense of $95.6 million, with $1.1535 billion of cash, equivalents and marketable securities at September 30 and funding guided into 2029. The azetukalner application for focal seizures, submitted in September, awaits FDA filing review. New enrollment in psychiatry studies stays paused, but X-NOVA2 enrollment is complete at about 360 patients and topline results are now guided to December 2026. The shares closed at $40.45 on November 9, before the release, and at $41.39 on November 10.

Last updated: November 10, 2026Market reference: November 10, 2026 regular-session closeFinancial period: September 30, 2026; share count November 5, 2026Research report date: November 9, 2026Currency: USD
Full research report · PDF
Xenon Pharmaceuticals research · November 10, 2026
23 pages covering the business, the third-quarter 2026 accounts, financial resources, catalysts, the November 10 close and the conference schedule, risks and sources. A dated edition for personal use; redistribution prohibited.
Get the report (PDF)
Next dated catalyst

Third quarter, reported November 9, 2026: net loss of $110.4 million, or $1.11 per share, on research and development of $95.6 million and other income of $11.5 million; cash, equivalents and marketable securities were $1,153.5 million at September 30, 2026, with funding into 2029. Release, November 9, 2026

December 2026 · X-NOVA2 topline results in major depressive disorder

Xenon completed enrollment in the Phase 3 X-NOVA2 study in major depressive disorder with about 360 patients and now expects topline data in December 2026, earlier than the first quarter of 2027 previously guided. New enrollment in the MDD and bipolar-depression studies remains voluntarily paused after an analysis of neuropsychiatric adverse events; participants already enrolled stay active, and the epilepsy studies continue. Q3 2026 release, November 9, 2026

Also scheduled: new azetukalner and epilepsy data at the American Epilepsy Society 2026 Annual Meeting in Denver, December 4–8, 2026, and investor conferences on November 11 (Stifel, New York), November 18 (Jefferies, London) and December 1 (Evercore, Coral Gables), after the fireside chat scheduled at the Guggenheim conference in Boston on November 10. Planned: initiation of the Phase 3b/4 X-FIRST study in the first quarter of 2027. Company schedule and pipeline
Xenon Pharmaceuticals XENE daily stock chart
Daily chart $XENE. Interactive chart with bull and bear scenarios on JC Just Charts →

XENE stock at a glance

Regular-session closing price
41.39
USD per share · 2026-11-10 · November 10, 2026 regular-session close; previous close $40.45.
Reference equity value
4,068,005,140.26
USD · 2026-11-10 · Calculated as $41.39 multiplied by 98,284,734 common shares reported outstanding on November 5, 2026. The share count and price have different reference dates.
Primary source
Cash, equivalents and marketable securities
1,153.5
USD million · 2026-09-30 · $950.8 million current and $202.7 million non-current; funding guided into 2029.
Primary source
Net loss
110.4
USD million · Q3 2026 · $1.11 per share, against $90.9 million and $1.15 a year earlier.
Primary source
Operating cash used
274.6
USD million · Nine months ended September 30, 2026, against $197.6 million a year earlier.
Primary source
Common shares and pre-funded warrants
98,284,734 common shares reported on November 5; 1,507,885 pre-funded warrants outstanding at September 30.
securities · 2026-11-05
Primary source
X-TOLE2 primary endpoint
53.2% median seizure reduction at 25 mg versus 10.4% with placebo over twelve weeks.
X-TOLE2 topline announcement, March 9, 2026
Primary source
Research and development expense
95.6
USD million · Quarter ended September 30, 2026, against $77.1 million a year earlier.
Primary source

Where Xenon Pharmaceuticals stands now

The focal-seizure application brings randomized X-TOLE and X-TOLE2 evidence into the regulatory review that follows submission. In X-TOLE2, median monthly seizure reduction over twelve weeks was 53.2% with 25 mg and 34.5% with 15 mg, compared with 10.4% on placebo. A future regulatory decision and approved instructions would define the scope of the commercial opportunity.

Xenon is preparing for that possibility while reassessing psychiatric dosing and developing earlier pain candidates. Cash, equivalents and marketable securities were $1,153.5 million at September 30, 2026, after $274.6 million of cash used in operations over the first nine months. The third quarter produced a $110.4 million net loss, or $1.11 per share, and management guided to funding operations into 2029 under its operating plan. New enrollment in the depression studies stays paused, but X-NOVA2 enrollment is complete at about 360 patients. Third-quarter 2026 release.

Azetukalner accounts for much of the nearer clinical and commercial opportunity. The psychiatric enrollment pause highlights the need to understand tolerability by population and regimen, while the epilepsy application retains its own regulatory assessment. With X-NOVA2 enrollment closed at about 360 patients, the topline readout now guided to December 2026 should answer the tolerability question within weeks rather than quarters. A successful approval would still require reliable supply, patient access and sustained prescribing to justify launch expenditure.

The constructive case

A satisfactory focal-seizure regulatory outcome and a practical oral product profile support a durable specialist launch. The balance sheet permits disciplined development, while pain programs add longer-term options.

The cautious case

Psychiatric tolerability and concentration around one molecule can narrow future opportunities. A December 2026 X-NOVA2 readout that fails to separate from placebo, or that carries an adverse-event profile the company cannot manage, would remove the psychiatry optionality while spending continues. Labeling, competition, patient access and sustained expenditure can absorb resources despite a strong reported balance.

Read also: Praxis $PRAX $RAPP $STOK $XENE: Beyond Seizure Counts →

Latest Xenon Pharmaceuticals news

Nov 9, 2026

Xenon reports Q3 2026 financial results and provides business update

Xenon reported a net loss of $110.4 million for the quarter ended September 30, 2026, compared to $90.9 million for the same period in 2025. Cash, cash equivalents and marketable securities were $1,153.5 million, with cash expected to fund operations into 2029. The company submitted its New Drug Application for azetukalner in focal seizures to the FDA in September 2026, and the topline data readout from the Phase 3 X-NOVA2 study in MDD is now expected in December 2026.

Nov 3, 2026

Xenon to present at upcoming investor conferences

Xenon Pharmaceuticals will present at four investor conferences in the fourth quarter of 2026, each as a fireside chat. The events are the Guggenheim 3rd Annual Healthcare Innovation Conference in Boston, MA on November 10, 2026; the Stifel 2026 Healthcare Conference in New York, NY on November 11, 2026; the 2026 Jefferies Global Healthcare Conference in London, UK on November 18, 2026; and the 9th Annual Evercore Healthcare Conference in Coral Gables, FL on December 1, 2026. Dates and times are subject to change, and webcasts will be posted for replay on the Investors section of Xenon's website.

Nov 2, 2026

Xenon to Report Q3 2026 Financial Results on November 9, 2026

Xenon Pharmaceuticals will report its third quarter 2026 financial results and provide a business update after the close of U.S. financial markets on Monday, November 9, 2026. A live webcast of the company presentation will be available on the Investors section of Xenon's website and posted for replay afterward. The dates and times are subject to change.

Oct 30, 2026

Employee inducement equity awards disclosed

Xenon disclosed inducement equity grants for newly hired employees under Nasdaq Listing Rule 5635(c)(4).

Oct 29, 2026

Pain programs prepare for Phase 2 proof of concept

Phase 1 and preclinical findings for XEN1701 and XEN1120 support plans to start acute-pain proof-of-concept studies in the first half of 2027.

Oct 2, 2026

New-employee inducement grants

Eight new non-officer employees received 17,850 options and 10,500 restricted share units, effective October 1, 2026.

XENE stock catalysts

  • December 2026 · X-NOVA2 topline results in major depressive disorderCompany guidance, November 9, 2026 · enrollment complete at about 360 patients

    Earlier than the first quarter of 2027 previously guided. Q3 2026 release

  • November 9, 2026 · Third-quarter 2026 results reportedReported · after the U.S. close

    Net loss of $110.4 million, or $1.11 per share; cash and securities of $1,153.5 million at September 30. Form 8-K, Exhibit 99.1

  • November 10, 2026 · Fireside chat, Guggenheim 3rd Annual Healthcare Innovation Conference, BostonCompany-announced · scheduled date passed

    Company schedule

  • November 11, 2026 · Fireside chat, Stifel 2026 Healthcare Conference, New YorkCompany-announced · date subject to change

    Company schedule

  • November 18, 2026 · Fireside chat, Jefferies Global Healthcare Conference, LondonCompany-announced · date subject to change

    Company schedule

  • December 1, 2026 · Fireside chat, 9th Annual Evercore Healthcare Conference, Coral GablesCompany-announced · date subject to change

    Company schedule

  • December 4–8, 2026 · American Epilepsy Society 2026 Annual Meeting, DenverCompany-announced · new azetukalner and epilepsy data expected

    Q3 2026 release

  • 2026 · X-TOLE3 enrollment outside Japan expected to completeCompany guidance, November 9, 2026

    Q3 2026 release

  • 2027-Q1 · Initiation of the Phase 3b/4 X-FIRST study in focal seizuresCompany target, November 9, 2026

    Q3 2026 release

  • 2027-H1 · Initiation of XEN1701 and XEN1120 acute-pain phase 2 proof-of-concept studiesCompany target announced October 29, 2026

    Details and conditions

  • 2027-04 · X-ACKT primary completionClinicalTrials.gov estimate; primary completion differs from a results announcement

    Details and conditions

  • 2028-01 · X-TOLE3 primary completionClinicalTrials.gov estimate; primary completion differs from a results announcement

    Details and conditions

  • Unscheduled · FDA filing review and any assigned application-review targetNDA submitted September 2026; subsequent regulatory milestone

    Details and conditions

  • Unscheduled · Psychiatry dose-regimen reassessment and enrollment plansNew enrollment paused since September 2026

    Q3 2026 release

Azetukalner programs occupy different stages

ProgramCurrent positionNext information
Focal seizuresNDA submitted September 17, 2026, supported by randomized X-TOLE and X-TOLE2 studies; awaiting FDA filing reviewFiling acceptance, any assigned review target and a future decision
Major depressive disorderX-NOVA2 enrollment complete at about 360 participants; new enrollment in the psychiatry studies paused since September 2026Topline results guided to December 2026
Broader epilepsyX-TOLE3 and X-ACKT continue development; X-FIRST planned as a Phase 3b/4 first-add-on studyX-TOLE3 enrollment outside Japan expected to complete in 2026; X-FIRST planned for the first quarter of 2027

Financial resources and ownership have different reference dates

MeasureReported valueReference
Cash, equivalents and marketable securities$1,153.5 millionSeptember 30, 2026
Operating cash used$274.617 millionNine months ended September 30, 2026
Common shares98,284,734November 5, 2026
Pre-funded warrants1,507,885September 30, 2026

Merlintrader Health Score · $XENE

3.30out of 5
Balance sheet / runway · 30%4

Cash, equivalents and marketable securities were $1,153.5 million at September 30, 2026, after $274.6 million of operating cash use in the first nine months, and Xenon guided to funding operations into 2029. Multiple studies and a possible first launch still require substantial spending.

Catalyst · 30%3

The focal-seizure NDA submitted in September awaits FDA filing review, and X-NOVA2 topline results are now guided to December 2026 after enrollment closed at about 360 patients. Both outcomes are binary and the psychiatry path remains unresolved.

Dilution · 20%3

Common shares rose to 98,275,278 at September 30 from 80,010,790 at December 31, 2025 after the March offering and $130.0 million of at-the-market sales completed by February 26; 1,507,885 pre-funded warrants, employee awards and a $400 million at-the-market authorization create continuing potential dilution.

Liquidity · 10%3

The Nasdaq-listed shares closed at $41.39 on November 10, 2026, and 98,284,734 common shares imply a reference equity value near $4.07 billion. A single session provides limited information about execution under event-driven volatility.

Execution · 10%3

Xenon submitted the NDA and completed X-NOVA2 enrollment, while new psychiatry enrollment stays paused pending a dose-regimen reassessment and X-FIRST is planned for the first quarter of 2027. A first launch still requires effective delivery.

Reassessed November 10, 2026, on the third-quarter 2026 results and the November 10 close; pillar scores unchanged from the November 9 assessment: 0.3 × 4 + 0.3 × 3 + 0.2 × 3 + 0.1 × 3 + 0.1 × 3 = 3.3. An editorial assessment of financial and operating resilience over twelve to eighteen months; no price target or recommendation is implied.

Red flags

  • The focal-seizure regulatory decision and eventual prescribing instructions remain ahead.
  • New psychiatry enrollment is paused while Xenon evaluates possible dosing changes; the December 2026 X-NOVA2 readout is the next test of that program.
  • Several opportunities depend on the same lead molecule, concentrating clinical and commercial exposure.
  • A first launch could increase spending before product revenue becomes meaningful; operating cash use reached $274.6 million in the first nine months of 2026.
  • Common shares rose 22.8 per cent from December 31, 2025 to September 30, 2026, and pre-funded warrants, employee awards and future issuance can dilute existing owners further.
  • Early pain studies have established exposure and tolerability information; patient analgesic efficacy remains to be tested.
  • Registry completion estimates are planning dates and can differ from company readout guidance.

XENE Stock FAQ: Xenon Pharmaceuticals Questions Answered

What is the next XENE stock catalyst?

Xenon now guides X-NOVA2 topline results in major depressive disorder to December 2026, after completing enrollment with about 360 patients; the earlier guidance was the first quarter of 2027 (Q3 2026 release, November 9, 2026). The company also expects new azetukalner and epilepsy data at the American Epilepsy Society annual meeting in Denver on December 4–8, 2026, and plans to start the Phase 3b/4 X-FIRST study in the first quarter of 2027. The focal-seizure application submitted in September remains with the FDA, with filing acceptance and any review goal date still unannounced. Q3 2026 release. Company schedule and pipeline.

Is Xenon’s azetukalner FDA approved for focal seizures?

No: azetukalner is not approved for any indication as of November 10, 2026. Xenon submitted the focal-seizure New Drug Application in September 2026 and restated the submission in its third-quarter results release; a submission does not grant marketing approval. Filing review, substantive assessment and a future decision remain ahead, and X-TOLE3 and X-ACKT are continuing epilepsy studies. Q3 2026 development update. NDA submission and epilepsy program.

How much cash does Xenon Pharmaceuticals have, and how long will it last?

Xenon held $1,153.5 million of cash, equivalents and marketable securities at September 30, 2026 and guided to funding operations into 2029 under its operating plan (Q3 2026 results, November 9, 2026). Of that total, $950.8 million was classified as current and $202.7 million as non-current, against $586.0 million at December 31, 2025. Operating cash use was $274.6 million in the first nine months of 2026. Q3 2026 release. Form 10-Q, cash-flow statement.

Could XENE stock be diluted by new shares or warrants?

Xenon reported 98,284,734 common shares outstanding at November 5, 2026 and 1,507,885 pre-funded warrants at September 30, 2026; the at-the-market program permits up to $400 million of gross common-share sales, and employee awards add further potential dilution (Form 10-Q, November 9, 2026). Common shares rose from 80,010,790 at December 31, 2025, after the March offering and after $130.0 million of at-the-market sales completed by February 26, 2026. Share capital, warrants and at-the-market program.

When does Xenon Pharmaceuticals report earnings?

Xenon reported third-quarter 2026 results after the U.S. market close on November 9, 2026: a net loss of $110.4 million, or $1.11 per share, with $1,153.5 million of cash and securities (Q3 2026 release, November 9, 2026). The date of the fourth-quarter and full-year 2026 report has not been announced. Third-quarter 2026 results.

What does Xenon Pharmaceuticals do?

As of November 10, 2026, Xenon is a neuroscience-focused biotechnology company developing treatments for epilepsy, psychiatric disorders and pain. Its lead program, azetukalner, opens KV7 potassium channels and is in late-stage development, with a focal-seizure New Drug Application awaiting FDA filing review. Potassium- and sodium-channel programs for pain are in Phase 1, with Phase 2 proof-of-concept studies planned for the first half of 2027. Company and pipeline overview. Lead-program regulatory stage.

Why did Xenon pause enrollment in depression studies?

Xenon paused new enrollment in its Phase 3 psychiatry studies in September 2026 after an analysis of neuropsychiatric adverse events; participants already enrolled remained active and the epilepsy studies were unaffected. On November 9, 2026 the company said X-NOVA2 enrollment in major depressive disorder is complete with about 360 patients and topline results are now expected in December 2026, while the pause on new enrollment continues and dosing is being reassessed. Q3 2026 update on the psychiatry program. September 2026 announcement.

When will Xenon start the XEN1701 and XEN1120 pain trials?

Xenon targets initiation of Phase 2 proof-of-concept studies of XEN1701 and XEN1120 in acute pain during the first half of 2027, a plan repeated in its November 9, 2026 results release. Phase 1 findings concern safety, tolerability and drug exposure in healthy participants. Supportive animal-model findings are preclinical evidence, rather than proof of pain relief in patients. Q3 2026 pain-program update. October 2026 findings.

Primary sources and market references

Disclaimer. Published by Merlintrader for educational and informational purposes only. This content does not constitute investment advice or a recommendation to buy, sell or hold securities. Verify figures against the dated primary disclosures. Investors can lose part or all of their capital.

Neuroscience drug development involves clinical, safety, regulatory, manufacturing, access and competitive risks. Trials may fail or require additional work, product approval and successful commercialization are uncertain, and continued development can consume substantial cash. Equity financing and employee awards can dilute shareholders, while concentration around a lead molecule can connect risks across several indications.

Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz, which may generate a commission at no cost to the reader. Full legal information: disclaimer and terms of use and privacy.